{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:30Z","timestamp":1790240550442,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.thromres.2026.109805","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:49:10Z","timestamp":1787294950000},"page":"109805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Direct oral anticoagulants versus vitamin K antagonists after venous thrombosis in antiphospholipid syndrome: Recurrence, safety, and exploratory phenotype analysis. A real-life cohort study"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-6432","authenticated-orcid":false,"given":"Ariela","family":"Hoxha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gobbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Spiezia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scarinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Zanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9fan","family":"Zuily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2026.109805_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2026.109805_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite ntiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109805_bb0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109805_bb0020","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109805_bb0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2026.109805_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19635","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","author":"Arachchillage","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.thromres.2026.109805_bb0035","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1016\/S2352-3026(20)30116-2","article-title":"Management of anticoagulant-refractory thrombotic antiphospholipid syndrome","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.thromres.2026.109805_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002881","article-title":"Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study","volume":"9","author":"Guedon","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.thromres.2026.109805_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103180","article-title":"Risk factors for damage accrual in primary antiphospholipid syndrome: a retrospective single-center cohort study","volume":"144","author":"Hoxha","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.thromres.2026.109805_bb0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109805_bb0055","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109805_bb0060","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/rheumatology\/keac485","article-title":"Predictive value of the adjusted global anti-phospholipid syndrome score on clinical recurrence in APS patients: a longitudinal study","volume":"62","author":"Barilaro","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2026.109805_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","author":"Meroni","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109805_bb0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109805_bb0075","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomized, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.thromres.2026.109805_bb0080","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109805_bb0085","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2026.109805_bb0090","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2026.109805_bb0095","author":"Pharmacovigilance Risk Assessment Committee of the European Medicines Agency"},{"key":"10.1016\/j.thromres.2026.109805_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11239-021-02587-0","article-title":"Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome","volume":"54","author":"Williams","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2026.109805_bb0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/FJC.0000000000001578","article-title":"Apixaban versus vitamin K antagonists in patients with antiphospholipid syndrome: a cohort study","author":"Sikorska","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.thromres.2026.109805_bb0110","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.3324\/haematol.2017.185132","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban","author":"Martinelli","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2026.109805_bb0115","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0961203319881200","article-title":"Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study","volume":"28","author":"Sato","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109805_bb0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s11239-021-02578-1","article-title":"Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism","volume":"53","author":"Kwan","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2026.109805_bb0125","article-title":"A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome","volume":"6","author":"Legault","year":"2020","journal-title":"Pilot Feasibility Stud."},{"key":"10.1016\/j.thromres.2026.109805_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164845","article-title":"Thromboembolic Antiphospholipid Syndrome (APS): efficacy and safety of different anticoagulants-results of the APSantiCO Registry","volume":"11","author":"Schulz","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.thromres.2026.109805_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ejh.13770","article-title":"Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome","volume":"109","author":"Liu","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2026.109805_bb0140","first-page":"476","article-title":"Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism","author":"Sciascia","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2026.109805_bb0145","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109805_bb0150","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109805_bb0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0039-1697665","article-title":"Upgrading therapy strategy improves pregnancy outcome in antiphospholipid syndrome: a cohort management study","volume":"120","author":"Hoxha","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109805_bb0160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0961203315576858","article-title":"Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)","volume":"24","author":"Amigo","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109805_bb0165","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2026.109805_bb0170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"10.1016\/j.thromres.2026.109805_bb0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2026.109805_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1721515","article-title":"Terrible APS - a newly defined variant of severe APS","volume":"16","author":"Niznik","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2026.109805_bb0185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/09612033251322927","article-title":"Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapy","volume":"34","author":"Gaspar","year":"2025","journal-title":"Lupus"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:17:22Z","timestamp":1790237842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826002240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0049384826002240"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109805","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants versus vitamin K antagonists after venous thrombosis in antiphospholipid syndrome: Recurrence, safety, and exploratory phenotype analysis. A real-life cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109805"}}